In an interview with CNBC-TV18, Vishal Manchanda of Nirmal Bang Institutional Equities spoke about the observations and gave his views on the stock.
CNBC TV18
@moneycontrolcom
CNBC-TV18 accessed form 483 issued to Sun Pharmaceutical's Halol facility where the US drug regulator has issued 3 observations.
In an interview with CNBC-TV18, Vishal Manchanda of Nirmal Bang Institutional Equities spoke about the observations and gave his views on the stock.
We got the observations reviewed by a consultant and the opinion is largely that these are minor, so they can get through in a shorter timeframe, he said.
